ALISO VIEJO, Calif., Feb. 22 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced fourth quarter and full year financial results for 2009. "Across the organization, Valeant delivered on its commitments in 2009," stated J. Michael Pearson, chairman and chief executive officer. "We intend to continue our strong performance in 2010, with a focus on growth through market-driven innovation, improvements in our operating leverage, and the progression of our pipeline products."
